Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

B Schultheis, G Folprecht, J Kuhlmann, R Ehrenberg, U T Hacker, C H Köhne, M Kornacker, O Boix, J Lettieri, J Krauss, R Fischer, S Hamann, D Strumberg, K B Mross, B Schultheis, G Folprecht, J Kuhlmann, R Ehrenberg, U T Hacker, C H Köhne, M Kornacker, O Boix, J Lettieri, J Krauss, R Fischer, S Hamann, D Strumberg, K B Mross

Abstract

Background: Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase inhibitor, regorafenib, was combined with chemotherapy as first- or second-line treatment of mCRC to assess safety and pharmacokinetics (primary objectives) and tumor response (secondary objective).

Patients and methods: Forty-five patients were treated every 2 weeks with 5-fluorouracil 400 mg/m(2) bolus then 2400 mg/m(2) over 46 h, folinic acid 400 mg/m(2), and either oxaliplatin 85 mg/m(2) or irinotecan 180 mg/m(2). On days 4-10, patients received regorafenib 160 mg orally once daily.

Results: The median duration of treatment was 108 (range 2-345 days). Treatment was stopped for adverse events or death (17 patients), disease progression (11 patients), and consent withdrawal or investigator decision (11 patients). Six patients remained on regorafenib at data cutoff (two without chemotherapy). Drug-related adverse events occurred in 44 patients [grade ≥ 3 in 32 patients: mostly neutropenia (17 patients) and leukopenia, hand-foot skin reaction, and hypophosphatemia (four patients each)]. Thirty-three patients achieved disease control (partial response or stable disease) for a median of 126 (range 42-281 days).

Conclusion: Regorafenib had acceptable tolerability in combination with chemotherapy, with increased exposure of irinotecan and SN-38 but no significant effect on 5-fluorouracil or oxaliplatin pharmacokinetics.

Trial registration: ClinicalTrials.gov NCT01289821 NCT01298570.

Keywords: chemotherapy; colorectal cancer; combination therapy; regorafenib; tyrosine kinase inhibition.

Figures

Figure 1.
Figure 1.
Time to progression in patients with disease progression or “censored at last contact”.

References

    1. Globocan. Colorectal Cancer Fact Sheet 2008. Lyon, France: International Agency for Research on Cancer; 2010.
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Version 3.2012. Fort Washington, PA: National Comprehensive Cancer Network; 2012.
    1. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;21(Suppl 2):v93–v97.
    1. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721–5727.
    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
    1. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842–1847.
    1. Ocvirk J, Brodowicz T, Wrba F, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol. 2010;16:3133–3143.
    1. Meyerhardt JA, Stuart K, Fuchs CS, et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007;18:1185–1189.
    1. Tol J, Koopman M, Cat M, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–572.
    1. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–255.
    1. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–2667.
    1. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–1727.
    1. Grothey A, Cutsem EV, Sobrero A, et al. for the CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:303–312.
    1. Schultheis B, Folprecht G, Kuhlmann J, et al. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in first-/second-line colorectal cancer patients. American Society of Clinical Oncology Annual Meeting; Chicago, IL, USA: 2011. Abstract 3585.
    1. Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM); 2001. .
    1. Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205–1218.
    1. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237.
    1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–1047.
    1. Shimizu T, Satoh T, Tamura K, et al. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol. 2007;12:218–223.
    1. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
    1. Ma J, Pulfer S, Li S, et al. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001;61:5491–548.
    1. Fenton BM, Paoni SF, Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol. 2004;72:221–230.
    1. Hu-Lowe D, Athias A, Hall C, et al. Impact of dosing schedule and dosing sequence on anti-tumor efficacy of combination therapy with the antiangiogenic agent (AA) axitinib (AG-013736) in xenograft tumor models of human pancreatic carcinoma and non-small cell lung cancer (NSCLC). AACR Annual Meeting 2009; ; Denver: American Association for Cancer Research, Abstract 144.
    1. Troiani T, Serkova NJ, Gustafson DL, et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res. 2007;13:6450–6458.
    1. Christensen JG. Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. AACR Annual Meeting 2009; ; Denver: American Association for Cancer Research, Abstract 1433.
    1. Starling N, Vázquez-Mazón F, Cunningham D, et al. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol. 2012;23:119–127.
    1. Mross K, Büchert M, Fasol U, et al. A preliminary report of a phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment—a study of the CESAR Central European Society for Anticancer Drug Research. Int J Clin Pharmacol Ther. 2011;49:96–98.
    1. . Study of FOLFIRI Chemotherapy with or without Sunitinib in Patients with Metastatic Colorectal Cancer. . 23rd August 2012, date last accessed.
    1. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer. 2005;5:188–196.
    1. Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer. 2007;43:55–63.
    1. Schultheis B, Kummer G, Zeth M, et al. Phase Ib study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2012;69:333–339.
    1. Hecht JR, Trarbach T, Hainsworth JD, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29:1997–2003.
    1. Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011;29:2004–2010.
    1. . Leucovorin and Fluorouracil with or without SU5416 in Treating Patients with Metastatic Colorectal Cancer. . 23rd August 2012, date last accessed.
    1. Siu LL, Shapiro JD, Jonker DJ, et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): the NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol. 2012;30(Suppl 4) 3504.
    1. Robertson JD, Botwood NA, Rothenberg ML, et al. Phase III Trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2009;8:59–60.
    1. Hoff PM, Hochhaus A, Pestalozzi BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II) J Clin Oncol. 2012;30:3596–3603.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit